Cendifensine

Cendifensine is an investigational oral small-molecule monoamine reuptake inhibitor being developed by Noema Pharma for the treatment of vasomotor symptoms associated with menopause, with additional exploration in binge‑eating disorder and depressive disorders.[2][3][12] Chemically related to amphetamines and cathinones, it functions as a broad‑spectrum monoamine modulator that inhibits the serotonin, norepinephrine, and dopamine transporters (SERT, NET, and DAT), thereby selectively enhancing central monoamine signaling.[2][3][9][11][12] By rebalancing monoaminergic tone and modulating KNDy neuron activity in hypothalamic thermoregulatory pathways, cendifensine aims to correct temperature dysregulation underlying hot flashes and night sweats while potentially improving other CNS‑mediated menopausal symptoms such as mood, fatigue, food cravings, and weight gain.[1][2][5] The drug has shown promising Phase 2a open‑label results with large reductions in hot flash frequency and severity and a favorable tolerability profile, but it has not yet been approved or marketed.[2][3][5][6][12]